Luteal Phase Dosing of Fluoxetine: Prescribing Strategy
For luteal phase dosing with an additional 10 mg fluoxetine on top of a baseline 20 mg daily regimen, prescribe fluoxetine 20 mg daily continuously throughout the entire menstrual cycle, then add fluoxetine 10 mg (for a total of 30 mg/day) during the luteal phase only—typically starting approximately 14 days before expected menses and continuing until menstruation begins.
Practical Prescribing Instructions
Write two separate prescriptions:
- Prescription 1: Fluoxetine 20 mg capsules, take 1 capsule by mouth every morning continuously (30-day supply)
- Prescription 2: Fluoxetine 10 mg capsules, take 1 capsule by mouth every morning during the luteal phase only—starting approximately 14 days before expected menses and stopping when menstruation begins (15-day supply per cycle, adjust quantity accordingly)
The patient takes 20 mg every day of the month, then adds the 10 mg capsule (total 30 mg) only during the luteal phase.
Evidence Base
Fluoxetine is FDA-approved for premenstrual dysphoric disorder (PMDD) 1, and the FDA label supports dosing flexibility above 20 mg/day, with doses administered either once daily or in divided doses 2. While the label doesn't explicitly detail luteal-phase-only augmentation strategies, it establishes that doses above 20 mg/day are safe and well-tolerated.
Luteal phase dosing strategies are well-supported in the literature. Research demonstrates that fluoxetine 20 mg given during the luteal phase alone is effective for PMDD 3, 4, and even lower doses (10 mg) during the luteal phase have shown benefit 3. Intermittent luteal-phase dosing (14 days premenstrually) with fluoxetine 20 mg has proven as effective as continuous daily dosing, with response rates of 75% 5. Multiple studies confirm that luteal phase administration reduces medication exposure and costs while maintaining efficacy comparable to continuous dosing 6.
Rationale for This Approach
The proposed regimen—continuous 20 mg with luteal augmentation to 30 mg—combines:
- Baseline symptom control: The continuous 20 mg provides steady-state coverage, which is particularly important given fluoxetine's long half-life (4-6 days for fluoxetine, 4-16 days for its active metabolite norfluoxetine)
- Luteal phase augmentation: The additional 10 mg during the luteal phase targets the symptomatic window when PMDD symptoms emerge
This strategy is more conservative than some studied regimens (e.g., 90 mg weekly dosing 7) but aligns with the principle that lower effective doses minimize side effects while maintaining therapeutic benefit.
Important Caveats
Fluoxetine's long half-life is critical to understanding luteal dosing. Unlike shorter-acting SSRIs (sertraline, paroxetine), fluoxetine accumulates over weeks and maintains relatively stable plasma levels even with intermittent dosing 3, 6. This pharmacokinetic property explains why intermittent dosing works for PMDD despite the typical 4-6 week delay in antidepressant effects seen in major depression.
Discontinuation symptoms are not reported with intermittent luteal dosing regimens 3, 6, which is a significant advantage over other SSRIs and makes this approach particularly suitable for cyclic administration.
Patient counseling should emphasize:
- The luteal phase typically begins around day 14 of a 28-day cycle (adjust based on individual cycle length)
- Symptoms usually improve within 1-3 menstrual cycles of treatment
- Side effects (nausea, headache, sexual dysfunction) are generally mild and transient 4
Alternative Considerations
If the patient is not already on fluoxetine 20 mg daily, consider starting with luteal-phase-only dosing (fluoxetine 20 mg for 14 days premenstrually) before committing to continuous therapy, as this approach has demonstrated 75% response rates 5 and reduces overall medication exposure.
For patients requiring higher doses, the FDA label supports up to 80 mg/day 2, and research has examined luteal dosing up to 60 mg daily 6 or even 90 mg given twice during the luteal phase 7.